Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1678
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2498
    -0.0013 (-0.10%)
     

  • Bitcoin GBP

    51,224.88
    -421.71 (-0.82%)
     

  • CMC Crypto 200

    1,332.28
    -64.26 (-4.60%)
     

  • S&P 500

    5,105.60
    +57.18 (+1.13%)
     

  • DOW

    38,296.46
    +210.66 (+0.55%)
     

  • CRUDE OIL

    83.74
    +0.17 (+0.20%)
     

  • GOLD FUTURES

    2,351.20
    +8.70 (+0.37%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

DTP Vaccines Global Market Report 2021: COVID-19 Growth And Change To 2030

ReportLinker
·3-min read

Major players in the DTP vaccines market are Merck & Co, Sanofi, GSK, Lanzhou Institute of Biological Products, Novartis AG, Pfizer Inc, Johnson & Johnson, Seqirus, AJ Vaccines, and Bionet-Asia.

New York, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "DTP Vaccines Global Market Report 2021: COVID-19 Growth And Change To 2030" - https://www.reportlinker.com/p06151679/?utm_source=GNW

The global DTP vaccines market is expected to grow from $3.95 billion in 2020 to $4.22 billion in 2021 at a compound annual growth rate (CAGR) of 6.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.3 billion in 2025 at a CAGR of 6%.

The DTP vaccines market consists of sales of vaccines used for the treatment of diphtheria, tetanus, and pertussis (whooping cough) and related services by entities (organizations, sole traders and partnerships) that produce vaccines for diphtheria, tetanus, and pertussis (whooping cough).The different types of vaccines available for these diseases include DTaP (diphtheria, tetanus, and acellular pertussis) vaccine, DT (diphtheria and tetanus) vaccine, Tdap (combined tetanus, diphtheria and acellular pertussis) vaccine and Td (tetanus and diphtheria) vaccine.

The market consists of revenue generated by the companies manufacturing DTP vaccines by the sales of these products.

The DTP vaccines market covered in this report is segmented by product type into DTaP, TD, Tdap. It is also segmented by disease into diphtheria, pertussis, tetanus and by end-user into hospitals, clinics, vaccination centers.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The inadequate access to vaccines in under-developed countries is expected to limit the growth of the DTP vaccines global market. According to the World Health Organization’s global estimates, around 19.4 million infants did not had access to DTP vaccines and around 60% of these children live in under-developed and developing countries. Countries such as the Central African Republic, Chad, Equatorial Guinea, Guinea, Samoa, Somalia, South Sudan, Syrian Arab Republic, and Ukraine have less than 50% coverage of DTP vaccination. Lack of access to vaccines in under-developed countries is expected to hamper the market growth.

In May 2020, Merck acquired Thermis, a company focused on vaccines and immuno-modulation therapies for infectious diseases, for an undisclosed amount.Thermis is involved in the discovery, development and production of vaccines with a sophisticated and versatile technology platform.

Merck is expected to leverage the vaccine technology enhanced by Thermis and the company will become a fully-owned subsidiary of Merck after completion of this deal.

Governments across the world are encouraging the R&D of DTP vaccines to disallow the spread of the diseases.Countries such as India have the Universal Immunisation Programme that aims to provide recommended vaccines against tuberculosis, polio and other diseases including diphtheria, tetanus and whooping cough for all Indian children.

The country regularly conducts vaccination drives, which is expected to positively impact the growth of the market. These initiatives are expected to drive the growth of the market in the forecast period.

Companies in the DTP vaccines market are increasingly investing in manufacturing DTP combination vaccines, which reduces multiple vaccination shots for immunization against infectious disease. DTP combination vaccines such as tetravalent (DTP-HepB), pentavalent (DTP-HepB-Hib) and hexavalent vaccine (DTP-Hib-HepB-IPV) are available to provide the same protection as individual vaccine shots given separately.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Read the full report: https://www.reportlinker.com/p06151679/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001